北京大学学报（医学版） ›› 2024, Vol. 56 ›› Issue (6): 947-949. doi: 10.19723/j.issn.1671-167X.2024.06.001
• 专家笔谈 • 下一篇
关注血栓性抗磷脂综合征的长期抗凝
李春*(
), 胡晓丹
- 北京大学人民医院风湿免疫科，北京 100044
春 李*(), 晓丹 胡
中图分类号:
- R593.2
| 1 |
Barilaro G , Esteves A , Della-Rocca C , et al. Predictive value of the adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: A longitudinal study[J]. Rheumatology (Oxford), 2023, 62 (4): 1576- 1585.
doi: 10.1093/rheumatology/keac485 |
| 2 |
Cervera R , Serrano R , Pons-Estel GJ , et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients[J]. Ann Rheum Dis, 2015, 74 (6): 1011- 1018.
doi: 10.1136/annrheumdis-2013-204838 |
| 3 |
Sevim E , Zisa D , Andrade D , et al. Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION international clinical database and repository[J]. Arthritis Care Res (Hoboken), 2022, 74 (2): 324- 335.
doi: 10.1002/acr.24468 |
| 4 |
Cervera R , Rodríguez-Pintó I , Espinosa G . The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review[J]. J Autoimmun, 2018, 92, 1- 11.
doi: 10.1016/j.jaut.2018.05.007 |
| 5 |
Tektonidou MG , Andreoli L , Limper M , et al. EULAR recommendations for the management of antiphospholipid syndrome in adults[J]. Ann Rheum Dis, 2019, 78 (10): 1296- 1304.
doi: 10.1136/annrheumdis-2019-215213 |
| 6 |
Crowther MA , Ginsberg JS , Julian J , et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome[J]. N Engl J Med, 2003, 349 (12): 1133- 1138.
doi: 10.1056/NEJMoa035241 |
| 7 |
Finazzi G , Marchioli R , Brancaccio V , et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)[J]. J Thromb Haemost, 2005, 3 (5): 848- 853.
doi: 10.1111/j.1538-7836.2005.01340.x |
| 8 |
Pengo V , Denas G , Zoppellaro G , et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome[J]. Blood, 2018, 132 (13): 1365- 1371.
doi: 10.1182/blood-2018-04-848333 |
| 9 |
Ordi-Ros J , Sáez-Comet L , Pérez-Conesa M , et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized noninferiority trial[J]. Ann Intern Med, 2019, 171 (10): 685- 694.
doi: 10.7326/M19-0291 |
| 10 |
Pengo V , Testa S , Martinelli I , et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant[J]. Thromb Res, 2015, 135 (1): 46- 49.
doi: 10.1016/j.thromres.2014.10.013 |
| 11 |
Yelnik CM , Urbanski G , Drumez E , et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity[J]. Lupus, 2017, 26 (2): 163- 169.
doi: 10.1177/0961203316657433 |
| 12 |
Mustonen P , Lehtonen KV , Javela K , et al. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study[J]. Lupus, 2014, 23 (14): 1468- 1476.
doi: 10.1177/0961203314545410 |
| 13 |
Ruffatti A , Del-Ross T , Ciprian M , et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: A prospective multicentre follow-up study[J]. Ann Rheum Dis, 2011, 70 (6): 1083- 1086.
doi: 10.1136/ard.2010.142042 |
| 14 |
Zuo Y , Barbhaiya M , Erkan D . Primary thrombosis prophylaxis in persistently antiphospholipid antibody-positive individuals: Where do we stand in 2018[J]. Curr Rheumatol Rep, 2018, 20 (11): 66.
doi: 10.1007/s11926-018-0775-8 |
| 15 |
Erkan D , Harrison MJ , Levy R , et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals[J]. Arthritis Rheum, 2007, 56 (7): 2382- 2391.
doi: 10.1002/art.22663 |
| 16 |
Arnaud L , Mathian A , Ruffatti A , et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis[J]. Autoimmun Rev, 2014, 13 (3): 281- 291.
doi: 10.1016/j.autrev.2013.10.014 |
| 17 |
Arnaud L , Mathian A , Devilliers H , et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies[J]. Autoimmun Rev, 2015, 14 (3): 192- 200.
doi: 10.1016/j.autrev.2014.10.019 |
| 18 |
Watanabe T , Oku K , Amengual O , et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies[J]. Lupus, 2018, 27 (2): 225- 234.
doi: 10.1177/0961203317716787 |
| 19 |
Erkan D , Willis R , Murthy VL , et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients[J]. Ann Rheum Dis, 2014, 73 (6): 1176- 1180.
doi: 10.1136/annrheumdis-2013-203622 |
| 20 |
Cohen H , Cuadrado MJ , Erkan D , et al. 16th International Congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends[J]. Lupus, 2020, 29 (12): 1571- 1593.
doi: 10.1177/0961203320950461 |
| 21 |
Erkan D , Unlu O , Sciascia S , et al. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease[J]. Lupus, 2018, 27 (3): 399- 406.
doi: 10.1177/0961203317724219 |
| 22 |
Cohen H , Sayar Z , Efthymiou M , et al. Management of anticoagulant-refractory thrombotic antiphospholipid syndrome[J]. Lancet Haematol, 2020, 7 (8): e613- e623.
doi: 10.1016/S2352-3026(20)30116-2 |
| 23 |
Mormile I , Granata F , Punziano A , et al. Immunosuppressive treatment in antiphospholipid syndrome: Is it worth it?[J]. Biomedicines, 2021, 9 (2): 132.
doi: 10.3390/biomedicines9020132 |
| 24 |
Rodríguez-Pintó I , Espinosa G , Erkan D , et al. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients[J]. Rheumatology (Oxford), 2018, 57 (7): 1264- 1270.
doi: 10.1093/rheumatology/key082 |
| 25 |
Berman H , Rodríguez-Pintó I , Cervera R , et al. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab[J]. Autoimmun Rev, 2013, 12 (11): 1085- 1090.
doi: 10.1016/j.autrev.2013.05.004 |
| 26 |
Yelnik CM , Miranda S , Mékinian A , et al. Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab[J]. Blood, 2020, 136 (21): 2473- 2477.
doi: 10.1182/blood.2020007499 |
| 27 | Bala MM , Celinska-Lowenhoff M , Szot W , et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome[J]. Cochrane Database Syst Rev, 2020, 10 (10): CD012169. |
| 28 |
Yelnik CM , Erton ZB , Drumez E , et al. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository ("Registry")[J]. Semin Arthritis Rheum, 2024, 65, 152347.
doi: 10.1016/j.semarthrit.2023.152347 |
| 29 |
Medina G , Briones-García E , Cruz-Domínguez MP , et al. Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence[J]. Autoimmun Rev, 2017, 16 (4): 352- 354.
doi: 10.1016/j.autrev.2017.02.004 |
| 30 |
Radin M , Schreiber K , Sciascia S , et al. Prevalence of antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: A long-term follow-up multicentre study[J]. Thromb Haemost, 2019, 119 (12): 1920- 1926.
doi: 10.1055/s-0039-1696687 |
| 31 |
Zen M , Loredo-Martinez M , Benvenuti F , et al. Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion[J]. Rheumatology (Oxford), 2021, 60 (3): 1313- 1320.
doi: 10.1093/rheumatology/keaa463 |
| 32 |
Cuadrado MJ , Tincani A , Enriquez-Merayo E , et al. Can anticoagulation be withdrawn in APS patients after aPL negativization[J]. Autoimmun Rev, 2024, 23 (1): 103427.
doi: 10.1016/j.autrev.2023.103427 |
| 33 |
Ballul T , Mageau A , Roland Nicaise P , et al. Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome[J]. Thromb Res, 2023, 224, 1- 3.
doi: 10.1016/j.thromres.2023.02.005 |
| 34 |
Perez-Sanchez C , Barbarroja N , Messineo S , et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus[J]. Ann Rheum Dis, 2015, 74 (7): 1441- 1449.
doi: 10.1136/annrheumdis-2013-204600 |
| [1] | 李钰锴, 王红彦, 罗靓, 李云, 李春. 抗磷脂抗体在白塞病合并血栓中的临床意义[J]. 北京大学学报（医学版）, 2024, 56(6): 1036-1040. |
| [2] | 金银姬, 刘蕊. 以肠系膜静脉血栓为突出表现的遗传性蛋白S缺乏症1例[J]. 北京大学学报（医学版）, 2024, 56(6): 1106-1109. |
| [3] | 朱玉静, 王磊, 吕成银, 谈文峰, 张缪佳. 抗EJ抗体阳性抗合成酶综合征相关间质性肺疾病复发的临床特征分析[J]. 北京大学学报（医学版）, 2024, 56(6): 980-986. |
| [4] | 万利, 张周沧, 丁嘉祥, 王梅. 中心静脉导管拔除后静脉空气栓塞1例[J]. 北京大学学报（医学版）, 2024, 56(5): 938-941. |
| [5] | 李雨清,王飚,乔鹏,王玮,关星. 经耻骨后尿道中段悬吊带术治疗女性复发性压力性尿失禁的中长期疗效[J]. 北京大学学报（医学版）, 2024, 56(4): 600-604. |
| [6] | 杨捷,冯杰莉,张树栋,马潞林,郑清. 经食管超声心动图在肾切除术联合Mayo Ⅲ~Ⅳ级静脉瘤栓取栓术不同手术方式中的临床作用[J]. 北京大学学报（医学版）, 2024, 56(4): 631-635. |
| [7] | 周恬静,刘秋萍,张明露,刘晓非,康佳丽,沈鹏,林鸿波,唐迅,高培. 基于马尔科夫模型的社区人群启动降压药物治疗预防心血管病的策略比较[J]. 北京大学学报（医学版）, 2024, 56(3): 441-447. |
| [8] | 汤晓菲,李永红,丁秋玲,孙卓,张阳,王育梅,田美伊,刘坚. 类风湿关节炎患者下肢深静脉血栓发病率及危险因素[J]. 北京大学学报（医学版）, 2024, 56(2): 279-283. |
| [9] | 洪丽荣,陈雨佳,江庆来,贾汝琳,李春,冯亮华. 新型血栓四项联合常规凝血指标预测抗磷脂综合征患者血栓形成的价值[J]. 北京大学学报（医学版）, 2023, 55(6): 1033-1038. |
| [10] | 姚中强,李常虹,李欣艺,郭苇,翟佳羽,刘蕊,魏慧,穆荣. 抗磷脂酰丝氨酸/凝血酶原抗体与不明原因复发性流产的相关性分析[J]. 北京大学学报（医学版）, 2023, 55(6): 1058-1061. |
| [11] | 卢情怡,艾尼扎提·哈斯木,李宇菲,李春. 抗神经酰胺抗体在抗磷脂综合征中的分布及临床意义[J]. 北京大学学报（医学版）, 2023, 55(6): 1139-1143. |
| [12] | 彭清,刘佳君,刘焱,尚华,唐果,韩雅欣,龙丽. Padua预测评分和血清白蛋白水平在评估风湿病住院患者静脉血栓栓塞中的应用[J]. 北京大学学报（医学版）, 2023, 55(4): 625-630. |
| [13] | 张明露,刘秋萍,巩超,王佳敏,周恬静,刘晓非,沈鹏,林鸿波,唐迅,高培. 阿司匹林用于心血管病一级预防的不同策略比较：一项马尔可夫模型研究[J]. 北京大学学报（医学版）, 2023, 55(3): 480-487. |
| [14] | 林浩,李菁华,杨潇,陈晓婷,史宇晖,常春,郝元涛,曹望楠. 中国成都男男性行为人群HIV暴露前预防用药行为-认知偏差现状及其影响因素[J]. 北京大学学报（医学版）, 2023, 55(3): 511-520. |
| [15] | 庄金满,李天润,李选,栾景源,王昌明,冯琦琛,韩金涛. Rotarex旋切导管在股腘动脉狭窄合并血栓形成中的应用[J]. 北京大学学报（医学版）, 2023, 55(2): 328-332. |
|
||
